The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Fibrodysplasia Ossificans Progressiva: Clinical and Genetic Aspects
Open accessAbstract
Fibrodysplasia ossificans progressiva (FOP) is a severely disabling heritable disorder of connective tissue characterized by congenital malformations of the great toes and progressive heterotopic ossification that forms qualitatively normal bone in characteristic extraskeletal sites. The worldwide prevalence is approximately 1/2,000,000. There is no ethnic, racial, gender, or geographic predilection to FOP. Children who have FOP appear normal at birth except for congenital malformations of the great toes. During the first decade of life, sporadic episodes of painful soft tissue swellings (flare-ups) occur which are often precipitated by soft tissue injury, intramuscular injections, viral infection, muscular stretching, falls or fatigue. These flare-ups transform skeletal muscles, tendons, ligaments, fascia, and aponeuroses into heterotopic bone, rendering movement impossible. Patients with atypical forms of FOP have been described. They either present with the classic features of FOP plus one or more atypical features [FOP plus], or present with major variations in one or both of the two classic defining features of FOP [FOP variants]. Classic FOP is caused by a recurrent activating mutation (617G>A; R206H) in the gene ACVR1/ALK2 encoding Activin A receptor type I/Activin-like kinase 2, a bone morphogenetic protein (BMP) type I receptor. Atypical FOP patients also have heterozygous ACVR1 missense mutations in conserved amino acids. The diagnosis of FOP is made by clinical evaluation. Confirmatory genetic testing is available. Differential diagnosis includes progressive osseous heteroplasia, osteosarcoma, lymphedema, soft tissue sarcoma, desmoid tumors, aggressive juvenile fibromatosis, and non-hereditary (acquired) heterotopic ossification. Although most cases of FOP are sporadic (noninherited mutations), a small number of inherited FOP cases show germline transmission in an autosomal dominant pattern. At present, there is no definitive treatment, but a brief 4-day course of high-dose corticosteroids, started within the first 24 hours of a flare-up, may help reduce the intense inflammation and tissue edema seen in the early stages of the disease. Preventative management is based on prophylactic measures against falls, respiratory decline, and viral infections. The median lifespan is approximately 40 years of age. Most patients are wheelchair-bound by the end of the second decade of life and commonly die of complications of thoracic insufficiency syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2011) · SpringerReference · doi:10.1007/springerreference_33432 · Cited by 2,510
Shore, E. M., Xu, M., Feldman, G. J., Fenstermacher, D. A., Cho, T.-J., Choi, I. H., Connor, J. M., Delai, P., Glaser, D. L., LeMerrer, M., et al. (2006) · Nature Genetics · doi:10.1038/ng1783 · Cited by 1,215
Self-citationKaplan, F. S., Xu, M., Seemann, P., Connor, J. M., Glaser, D. L., Carroll, L., Delai, P., Fastnacht-Urban, E., Forman, S. J., Gillessen-Kaesbach, G., et al. (2009) · Human Mutation · doi:10.1002/humu.20868 · Cited by 436
Self-citationIatrogenic Harm Caused by Diagnostic Errors in Fibrodysplasia Ossificans Progressiva
Kitterman, J. A., Kantanie, S., Rocke, D. M., & Kaplan, F. S. (2005) · Pediatrics · doi:10.1542/peds.2005-0469 · Cited by 259
Self-citationEarly Mortality and Cardiorespiratory Failure in Patients with Fibrodysplasia Ossificans Progressiva
Kaplan, F. S., Zasloff, M. A., Kitterman, J. A., Shore, E. M., Hong, C. C., & Rocke, D. M. (2010) · The Journal of Bone and Joint Surgery-American Volume · doi:10.2106/jbjs.i.00705 · Cited by 241
Self-citationShen, Q., Little, S. C., Xu, M., Haupt, J., Ast, C., Katagiri, T., Mundlos, S., Seemann, P., Kaplan, F. S., Mullins, M. C., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37412 · Cited by 216
Self-citationEarly Diagnosis of Fibrodysplasia Ossificans Progressiva
Kaplan, F. S., Xu, M., Glaser, D. L., Collins, F., Connor, M., Kitterman, J., Sillence, D., Zackai, E., Ravitsky, V., Zasloff, M., et al. (2008) · Pediatrics · doi:10.1542/peds.2007-1980 · Cited by 188
Self-citationThe Fibrodysplasia Ossificans Progressiva Lesion
Pignolo, R. J., Suda, R. K., & Kaplan, F. S. (2005) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1385/bmm:3:3-4:195 · Cited by 78
Self-citationImmunological Features of Fibrodysplasia Ossificans Progressiva and the Dysregulated BMP4 Pathway
Kaplan, F. S., Shore, E. M., Gupta, R. R., Billings, P. C., Glaser, D. L., Pignolo, R. J., Graf, D., & Kamoun, M. (2005) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1385/bmm:3:3-4:189 · Cited by 52
Self-citationMorphogen Receptor Genes and Metamorphogenes: Skeleton Keys to Metamorphosis
Kaplan, F. S., Groppe, J. C., Pignolo, R. J., & Shore, E. M. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.039 · Cited by 42
Self-citation
Cited by
Osteoimmunology: The conceptual framework unifying the immune and skeletal systems
Okamoto, K., Nakashima, T., Shinohara, M., Negishi-Koga, T., Komatsu, N., Terashima, A., Sawa, S., Nitta, T., & Takayanagi, H. (2017) · Physiological Reviews · doi:10.1152/physrev.00036.2016 · Cited by 534
Heterotopic Ossification: A Comprehensive Review
Meyers, C., Lisiecki, J., Miller, S., Levin, A., Fayad, L., Ding, C., Sono, T., McCarthy, E., Levi, B., & James, A. W. (2019) · JBMR Plus · doi:10.1002/jbm4.10172 · Cited by 506
Hatsell, S. J., Idone, V., Wolken, D. M. A., Huang, L., Kim, H. J., Wang, L., Wen, X., Nannuru, K. C., Jimenez, J., Xie, L., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4358 · Cited by 446
Heterotopic Ossification: Basic-Science Principles and Clinical Correlates
Ranganathan, K., Loder, S., Agarwal, S., Wong, V. W., Forsberg, J., Davis, T. A., Wang, S., James, A. W., & Levi, B. (2015) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.n.01056 · Cited by 395
Metadata
- Authors
- Pignolo, R. J., Shore, E. M., & Kaplan, F. S.
- Venue
- Orphanet Journal of Rare Diseases
- Published
- 2011
- Volume
- 6
- Issue
- 1
- Pages
- 80
- ISSN
- 1750-1172 (ISSN-L)
- OpenAlex
- W2169474931
- Cited by
- 305
- References
- 10
- FWCI
- 8.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fibrodysplasia Ossificans Progressiva: Clinical and Genetic Aspects. https://app.cochat.ai/papers/10.1186/1750-1172-6-80
- The paper
- Pignolo, R. J., Shore, E. M., & Kaplan, F. S. (2011). Fibrodysplasia Ossificans Progressiva: Clinical and Genetic Aspects. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/1750-1172-6-80
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.